| CXCR7 is highly expressed in acute lymphoblastic leukemia and potentiates CXCR4 response to CXCL12 RCC Melo, AL Longhini, CL Bigarella, MO Baratti, F Traina, P Favaro, ... PloS one 9 (1), e85926, 2014 | 72 | 2014 |
| Co-occurrence of DNMT3A, NPM1, FLT3 mutations identifies a subset of acute myeloid leukemia with adverse prognosis MF Bezerra, AS Lima, MR Piqué-Borràs, DR Silveira, JL Coelho-Silva, ... Blood, The Journal of the American Society of Hematology 135 (11), 870-875, 2020 | 65 | 2020 |
| Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412 P de Melo Campos, JA Machado-Neto, R Scopim-Ribeiro, V Visconte, ... Leukemia research 38 (10), 1245-1251, 2014 | 51 | 2014 |
| Molecular matching for Rh and K reduces red blood cell alloimmunisation in patients with myelodysplastic syndrome GAS Guelsin, C Rodrigues, JEL Visentainer, P de Melo Campos, F Traina, ... Blood Transfusion 13 (1), 53, 2015 | 44 | 2015 |
| De novo AML exhibits greater microenvironment dysregulation compared to AML with myelodysplasia-related changes MR Lopes, JKN Pereira, P de Melo Campos, JA Machado-Neto, F Traina, ... Scientific reports 7 (1), 40707, 2017 | 39 | 2017 |
| Stathmin 1 is involved in the highly proliferative phenotype of high-risk myelodysplastic syndromes and acute leukemia cells JA Machado-Neto, P de Melo Campos, P Favaro, M Lazarini, ... Leukemia research 38 (2), 251-257, 2014 | 38 | 2014 |
| Stathmin 1 is involved in the highly proliferative phenotype of high-risk myelodysplastic syndromes and acute leukemia cells JA Machado-Neto, P de Melo Campos, P Favaro, M Lazarini, ... Leukemia research 38 (2), 251-257, 2014 | 38 | 2014 |
| ANKHD1 silencing inhibits Stathmin 1 activity, cell proliferation and migration of leukemia cells JA Machado-Neto, M Lazarini, P Favaro, P de Melo Campos, ... Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1853 (3), 583-593, 2015 | 35 | 2015 |
| IL10 inversely correlates with the percentage of CD8+ cells in MDS patients MR Lopes, F Traina, P de Melo Campos, JKN Pereira, JA Machado-Neto, ... Leukemia Research 37 (5), 541-546, 2013 | 30 | 2013 |
| IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms P de Melo Campos, JA Machado-Neto, CA Eide, SL Savage, ... Oncotarget 7 (6), 6948, 2016 | 29 | 2016 |
| Stathmin 1 inhibition amplifies ruxolitinib-induced apoptosis in JAK2V617F cells JA Machado-Neto, P de Melo Campos, P Favaro, M Lazarini, ASS Duarte, ... Oncotarget 6 (30), 29573, 2015 | 21 | 2015 |
| Low Ten-eleven-translocation 2 (TET2) transcript level is independent of TET2 mutation in patients with myeloid neoplasms R Scopim-Ribeiro, JA Machado-Neto, P de Melo Campos, FS Niemann, ... Diagnostic pathology 11, 1-5, 2016 | 18 | 2016 |
| Abnormal Hedgehog pathway in myelodysplastic syndrome and its impact on patients’ outcome JM Xavier-Ferrucio, FV Pericole, MR Lopes, P Latuf-Filho, KSA Barcellos, ... haematologica 100 (12), e491, 2015 | 12 | 2015 |
| YAP1 expression in myelodysplastic syndromes and acute leukemias JA Machado-Neto, P de Melo Campos, ST Olalla Saad, F Traina Leukemia & lymphoma 55 (10), 2413-2415, 2014 | 12 | 2014 |
| Reduced expression of FLIPSHORT in bone marrow of low risk myelodysplastic syndrome P de Melo Campos, F Traina, ASS Duarte, I Lorand-Metze, FF Costa, ... Leukemia research 31 (6), 853-857, 2007 | 11 | 2007 |
| NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia R Scopim-Ribeiro, JA Machado-Neto, CA Eide, JL Coelho-Silva, ... Investigational New Drugs 39, 736-746, 2021 | 10 | 2021 |
| The U2AF homology motif kinase 1 (UHMK1) is upregulated upon hematopoietic cell differentiation I Barbutti, JA Machado-Neto, VC Arfelli, P de Melo Campos, F Traina, ... Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1864 (3), 959-966, 2018 | 10 | 2018 |
| MDR-1 and GST polymorphisms are involved in myelodysplasia progression B Palodetto, P de Melo Campos, BD Benites, MLLF Chauffaille, ... Leukemia Research 37 (8), 970-973, 2013 | 10 | 2013 |
| Differential profile of PIP4K2A expression in hematological malignancies K Lima, DM Ribeiro, P de Melo Campos, FF Costa, F Traina, STO Saad, ... Blood Cells, Molecules, and Diseases 55 (3), 228-235, 2015 | 8 | 2015 |
| Lack of association between MDM2 SNP309 and TP53 Arg72Pro polymorphisms with clinical outcomes in myelodysplastic syndrome. JA Machado-Neto, F Traina, P De Melo Campos, MF Andreoli-Risso, ... Neoplasma 59 (5), 530-535, 2012 | 8 | 2012 |
